Joanne Britto, Anne Holbrook, Haowei Sun, Christine Cserti-Gazdewich, Oksana Prokopchuk-Gauk, Cyrus Hsia, Karima Khamisa, Paul R Yenson, Michelle Sholzberg, Harold J Olney, Sudeep Shivakumar, David Jones, Hayley Merkeley, Jacqueline Costello, Erin Jamula, Donald M Arnold
INTRODUCTION: Immune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts and increased risk of bleeding. After corticosteroids with or without intravenous immune globulin (first-line treatment), second-line treatment options include rituximab, splenectomy, thrombopoietin receptor agonists (TPO-RAs), and fostamatinib. In Canada, the choice of second-line therapy is influenced by access to medications. The goals of this narrative review are to 1) summarize the evidence for the use of TPO-RAs and other second-line therapies in ITP and 2) highlight differences in public funding criteria for TPO-RAs across provinces and territories in Canada...
March 1, 2024: Clinical and Investigative Medicine. Médecine Clinique et Experimentale